Cytokinetics, Amgen increase scope of heart failure deal

Amgen and Cytokinetics agreed to expand an existing licensing deal centered on the experimental heart failure drug omecamtiv mecarbil and related compounds to include the Japanese market. The expanded deal entitles Cytokinetics to $25 million in upfront payment and as much as $50 million in milestone fees plus sales royalties.

View Full Article in:

Los Angeles Business Journal (free registration) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health